Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 166 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Day 36 Assessments Clear all
Completed Phase 2 Interventional Results available

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT03132532
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

The Back Pain Consortium Research Program Study

NCT04870957
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
PainGuide, MBSR, PT and exercise, Self -administered acupressure, Duloxetine, Pro-Diary monitor
Behavioral · Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 70 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Sep 30, 2026, 4:44 PM EDT
Recruiting Phase 3 Interventional

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

NCT07114874
View directory record Official record
Conditions
Schizophrenia
Interventions
NBI-1117568
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
50
States / cities
Bryant, Arkansas • Little Rock, Arkansas • Cerritos, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 4:44 PM EDT
Terminated Phase 3 Interventional Results available

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

NCT03199885
View directory record Official record
Conditions
Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
Interventions
Atezolizumab, Biopsy, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, Paclitaxel, Pertuzumab, Placebo Administration, Quality-of-Life Assessment, Trastuzumab
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
662
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Sep 30, 2026, 4:44 PM EDT
Active, not recruiting Phase 2 Interventional

RANKL Inhibition and Mammographic Breast Density

NCT04067726
View directory record Official record
Conditions
Dense Breasts
Interventions
Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 30, 2026, 4:44 PM EDT
Recruiting Early Phase 1 Interventional

Early Intervention in High Risk CCUS

NCT06802146
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, Cytopenia
Interventions
Inqovi
Drug
Lead sponsor
Lachelle D. Weeks, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Not applicable Interventional

Practical Application of Accelerated iTBS for MDD

NCT06113575
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder, Recurrent Episode, Severe, Major Depressive Disorder, Recurrent, Moderate
Interventions
NeuroStar TMS
Device
Lead sponsor
Sonder Behavioral Health and Wellness
Other
Eligibility
22 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 30, 2026, 4:44 PM EDT
Recruiting Phase 2 Interventional

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

NCT06510309
View directory record Official record
Conditions
Lymphoma, Marginal Zone Lymphoma, MZL
Interventions
Venetoclax, Rituximab
Drug
Lead sponsor
Gottfried von Keudell, MD PhD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke

NCT05369533
View directory record Official record
Conditions
Stroke
Interventions
Telerehabilitation, Sinemet Pill, Placebo
Device · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

NCT01196390
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
Drug · Other · Radiation + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
634
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 30, 2026, 4:44 PM EDT
Not yet recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 30, 2026, 4:44 PM EDT
Completed No phase listed Observational Results available

Evaluation of Long-term Buprenorphine Plasma Exposure

NCT03752528
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Blood sample collection, Urine sample collection
Diagnostic Test
Lead sponsor
Indivior Inc.
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT02064426
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Azusa, California • Long Beach, California • Lynwood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer

NCT00941915
View directory record Official record
Conditions
Prostate Cancer
Interventions
SBRT Prostate
Radiation
Lead sponsor
Duke University
Other
Eligibility
40 Years to 82 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

NCT02908477
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Adjuvant Radiation Therapy, Docetaxel, Cisplatin
Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

NCT01585402
View directory record Official record
Conditions
Arterial Calcification, CD73 Deficiency
Interventions
Etidronate, MRI Scan
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Noninvasive Markers of Functional Nausea in Children

NCT03593811
View directory record Official record
Conditions
Nausea
Interventions
Questionnaires, 4 channel electrogastrogram (EGG), 36 channel high resolution electrogastrogram (HR-EGG), Magnetogastrogram (MGG), Electrocardiogram (EKG), Ondansetron, Cyproheptadine Oral Tablet
Diagnostic Test · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 30, 2026, 4:44 PM EDT
Completed No phase listed Observational

Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL

NCT03263052
View directory record Official record
Conditions
Disorder Related to Renal Transplantation
Interventions
Tacrolimus XR (Envarsus)
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

NCT01137890
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Zonisamide, Placebo, Cocaine Hydrochloride, Neurocognitive and Performance Battery, Smoking Assessments
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 30, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

NCT04337827
View directory record Official record
Conditions
Post-transplant Lymphoproliferative Disorder
Interventions
Rituximab, Acalabrutinib, CT scans
Drug · Diagnostic Test
Lead sponsor
Deepa Jagadeesh
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

NCT00256750
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Sep 30, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

NCT04349371
View directory record Official record
Conditions
COVID, Coronavirus Infection
Interventions
Chloroquine, Placebo oral tablet
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 30, 2026, 4:44 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

NCT04175678
View directory record Official record
Conditions
Healthy Lifestyle, Obese, Men
Interventions
Diet, Exercise, Standard care
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

NCT02352896
View directory record Official record
Conditions
Leigh Syndrome
Interventions
EPI-743
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
Stanford University, California • Akron, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 30, 2026, 4:44 PM EDT